As above mentioned, several clinical trials have so far validated the clinical relevance of molecular MRD monitoring in NPM1-mutated AML patients (Table 2), trying to identify prognostic MRD thresholds and most relevant timepoints for collecting either BM or PB samples [30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73]. This evidence concerns the gene NPM1 and acute myeloid leukemia.